About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
COMPANY NEWS
Company
News
Dr. Reddy's Laboratories Ltd.
Change Company
BSE Code
500124
ISIN Demat
INE089A01031
Book Value
345.76
NSE Code
DRREDDY
Dividend Yield %
0.60
Market Cap
1119048.97
P/E
20.92
EPS
64.10
Face Value
1
1 Week
1 Month
3 Months
6 Months
1 Year
05-Jun-2025
Dr. Reddy's Laboratories, Alvotech enter into lic...
05-Jun-2025
Dr. Reddy’s Laboratories informs about press rel...
05-Jun-2025
Dr. Reddy's Laboratories soars on entering into l...
26-May-2025
USFDA completes GMP inspection at Dr. Reddy's Tel...
17-May-2025
USFDA completes GMP inspection at Dr. Reddy's API...
17-May-2025
Dr Reddys Laboratories informs about disclosure
10-May-2025
Dr. Reddy's Laboratories reports 21% rise in Q4 c...
10-May-2025
Dr Reddys Laboratories informs about press release
10-May-2025
Dr. Reddy’s Laboratories informs about audio reco...
09-May-2025
Dr Reddys Laboratories informs about dividend upd...
29-Apr-2025
Dr. Reddy's Laboratories expands partnership with...
23-Apr-2025
Dr. Reddy's arm recalling 4,010 bags of Levetirac...
16-Apr-2025
Dr. Reddy’s Laboratories informs about disclosure
27-Mar-2025
Dr. Reddy’s arm inks commercialization and licens...
24-Mar-2025
Dr. Reddy's arm sells membership interests in Dr....
Page
1
of
4
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.